About

About Fulgent Genetics Fulgent is a technology-driven Biopharma services company boasting a robust portfolio of clinical diagnostic, research solutions and R&D capabilities. Our clinical diagnostic and BioPharma business units provide a wide array of services including molecular diagnostic testing, comprehensive NGS genetic testing, RNASeq, targeted DNA / RNA panels (FFPE, Liquid Biopsy, Heme), single cell and spatial analysis (10x Genomics), proteomics (Olink) and top-tier anatomic pathology laboratory services (Immunohistochemistry (IHC), RNAscope (ISH), Akoya, Flow Cytometry). These offerings are meticulously crafted to support biomarker development in immuno-Oncology research complemented with actionable diagnostic insights, ultimately enhancing the quality of patient care. With a dedicated focus on patient screening and enrollment testing, biomarker analysis, and companion diagnostics for clinical research, Pharma Clinical trials, and contract research, Fulgent's BioPharma Services cater to the specific needs of the pharmaceutical industry. With facilities situated in the US, China, and Australia, our overarching mission is to revolutionize the genomic diagnostic landscape, positioning ourselves as a fully integrated precision medicine company poised to drive advancements in healthcare. Fulgent's latest step forward to this commitment is approval for the largest CE-marked Clinical Exome gene panel for genetic testing, underscoring our dedication to meeting the highest standards of regulatory compliance & quality. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.